Prescribing of bisphosphonates and antibiotics in Pakistan: Challenges and opportunities for the future

Journal of Pharmaceutical Health Services Research

Volumn 6, Issue 2, 2015, Pages 111-121

  Riaz, Humayun ^a   Godman, Brian ^b,c   Hussain, Shahzad ^d   Malik, Farnaz ^d   Mahmood, Sidra ^e,g   Shami, Ali ^f   Bashir, Sajid ^a  

^a UNIVERSITY OF SARGODHA   (Pakistan)

^b NATIONAL INSTITUTE OF HEALTH   (Pakistan)

^c QUAID I AZAM UNIVERSITY   (Pakistan)

^d PAKISTAN INSTITUTE OF MEDICAL SCIENCES   (Pakistan)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^g NONE   (Pakistan)

Author keywords

Antibiotics; Bisphosphonates; Generics; Influencing prescribing; Pakistan

Indexed keywords

ANTIBIOTIC AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; COLECALCIFEROL; GENERIC DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; SEDATIVE AGENT; STEROID; TRANQUILIZER;

ADULT; AGED; ARTICLE; CONSULTATION; COST BENEFIT ANALYSIS; CROSS-SECTIONAL STUDY; DRUG COST; FEMALE; HEALTH CARE FACILITY; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL EDUCATION; PAKISTAN; PATIENT ASSESSMENT; PATIENT CARE; PATIENT EDUCATION; PHARMACEUTICAL CARE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; SOCIAL STATUS;

EID: 84929288032     PISSN: 17598885     EISSN: 17598893     Source Type: Journal    
DOI: 10.1111/jphs.12091     Document Type: Article

References (108)

1. Tully MP, Cantrill JA. The validity of explicit indicators of prescribing appropriateness. Int J Qual Health Care 2006; 18: 87-94.
2. Campbell SM etal. Quality indicators as a tool in improving the introduction of new medicines. Basic Clin Pharmacol Toxicol 2015; 116(2): 146-157.
3. Babar ZU, Francis S. Identifying priority medicines policy issues for New Zealand: a general inductive study. BMJ Open 2014; 4: e004415.
4. Drews J. Drug discovery: a historical perspective. Science 2000; 287: 1960-1964.
5. Cameron A etal. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet 2009; 373: 240-249.
6. Jooma R. Pakistan Pharmaceutical Country Profile. http://www.who.int/medicines/areas/coordination/pakistan.pdf (accessed 22 June 2014).
7. World Health Organisation. Pakistan - Medicine Prices, Availability, Affordability and Price Components. http://www.haiweb.org/medicineprices/surveys/200407PK/sdocs/Pakistan-summary-report-web.pdf (accessed 22 June 2014).
8. Jamshed SQ etal. Perception and attitude of general practitioners regarding generic medicines in Karachi, Pakistan: a questionnaire based study. South Med Rev 2012; 5: 22-30.
9. Zaidi S etal. Access to essential medicines in Pakistan: policy and health systems research concerns. PLoS ONE 2013; 8: e63515.
10. Garattini S etal. Enhancing the rational use of new medicines across European health care systems. Eur J Clin Pharmacol 2008; 64: 1137-1138.
11. Mousnad MA etal. Systematic review of factors affecting pharmaceutical expenditures. Health Policy (New York) 2014; 116: 137-146.
12. Godman B etal. Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications. BMC Med 2014; 12: 1-12.
13. Godman B etal. Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs. Front Pharmacol 2014; 5: 1-11.
14. Woerkom M etal. Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications. J Comp Eff Res 2012; 1: 527-538.
15. Godman B etal. Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries. Expert Rev Pharmacoecon Outcomes Res 2013; 13: 469-482.
16. Godman B etal. Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications. Front Pharmacol 2014; 5: 1-9.
17. Cameron A, Laing R. Cost Savings of Switching Private Sector Consumption from Originator Brand Medicines to Generic Equivalents. http://www.who.int/healthsystems/topics/financing/healthreport/35MedicineCostSavings.pdf (accessed 25 November 2014).
18. Gustafsson LL etal. The 'wise list' - a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin Pharmacol Toxicol 2011; 108: 224-233.
19. Bjorkhem-Bergman L etal. Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations. Eur J Clin Pharmacol 2013; 69(Suppl.1): 73-78.
20. Rottenkolber D etal. Adverse drug reactions in Germany: direct costs of internal medicine hospitalizations. Pharmacoepidemiol Drug Saf 2011; 20: 626-634.
21. Pirmohamed M etal. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329: 15-19.
22. Miller I etal. Market access challenges in the EU for high medical value diagnostic tests. Personalised Medicine 2011; 8: 137-148.
23. Kesselheim AS, Outterson K. Fighting antibiotic resistance: marrying new financial incentives to meeting public health goals. Health Aff 2010; 29: 1689-1696.
24. Sabuncu E etal. Significant reduction of antibiotic use in the community after a nationwide campaign in France, 2002-2007. PLoS Med 2009; 6: e1000084.
25. Goossens H etal. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 2005; 365: 579-587.
26. Costelloe C etal. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. BMJ 2010; 340: c2096.
27. Fürst J etal. The influence of a sustained multifaceted approach to improve antibiotic prescribing in Slovenia during the past decade; findings and implications. Expert Rev Anti Infect Ther 2015; 13(2): 279-289.
28. Davey P etal. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev 2013; 4: Cd003543.
29. Huttner B etal. Characteristics and outcomes of public campaigns aimed at improving the use of antibiotics in outpatients in high-income countries. Lancet Infect Dis 2010; 10: 17-31.
30. Sumpradit N etal. Antibiotics smart use: a workable model for promoting the rational use of medicines in Thailand. Bull World Health Organ 2012; 90: 905-913.
31. Siddiqi S etal. Prescription practices of public and private health care providers in Attock District of Pakistan. Int J Health Plann Manage 2002; 17: 23-40.
32. Hussain SMF etal. Pharmacoepidemiological studies of prescribing practices of health care providers of Pakistan: a cross-sectional survey. Afr J Pharm Pharmacol 2011; 5: 1484-1493.
33. Godman B etal. Initiatives among authorities to improve the quality and efficiency of prescribing and the implications. J Pharma Care Health Sys 2014; 1(3): 1-15.
34. Wagner AK etal. Access to care and medicines, burden of health care expenditures, and risk protection: results from the World Health Survey. Health Policy 2011; 100: 151-158.
35. Li Y etal. Overprescribing in China, driven by financial incentives, results in very high use of antibiotics, injections, and corticosteroids. Health Aff (Millwood) 2012; 31: 1075-1082.
36. Teng CL etal. Antibiotic prescription in upper respiratory tract infections. Asia Pac Fam Med 2004; 3: 38-45.
37. Alabid AH etal. Antibiotics dispensing for URTIs by Community Pharmacists (CPs) and general medical practitioners in Penang, Malaysia: a comparative study using Simulated Patients (SPs). J Clin Diagn Res 2014; 8: 119-123.
38. Shiwani MH. Quest of prescribing practice in Pakistan. J Pak Med Assoc 2006; 56: 249-250.
39. Godman B etal. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert Rev Pharmacoecon Outcomes Res 2009; 9: 65-83.
40. Holloway KA, Henry D. WHO essential medicines policies and use in developing and transitional countries: an analysis of reported policy implementation and medicines use surveys. PLoS medicine. 2014; 11(9): e1001724.
41. Wettermark B etal. Financial incentives linked to self-assessment of prescribing patterns: a new approach for quality improvement of drug prescribing in primary care. Qual Prim Care 2009; 17: 179-189.
42. Norman C etal. Potential savings without compromising the quality of care. Int J Clin Pract 2009; 63: 1320-1326.
43. Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc 2011; 86: 304-314.
44. Haynes RB etal. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008; 2: Cd000011.
45. Cramer JA etal. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int J Clin Pract 2008; 62: 76-87.
46. Pont LG etal. Validity of performance indicators for assessing prescribing quality: the case of asthma. Eur J Clin Pharmacol 2004; 59: 833-840.
47. Patterson HR. The problems of audit and research. J R Coll Gen Pract 1986; 36: 196.
48. Sermet C etal. Ongoing pharmaceutical reforms in France: implications for key stakeholder groups. Appl Health Econ Health Policy 2010; 8: 7-24.
49. Hanley DA, Josse RG. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 1. Introduction. CMAJ 1996; 155: 921-923.
50. Zafran N etal. Incidence and causes for failure of treatment of women with proven osteoporosis. Osteoporos Int 2005; 16: 1375-1383.
51. Dawson-Hughes B etal. The potential impact of the National Osteoporosis Foundation guidance on treatment eligibility in the USA: an update in NHANES 2005-2008. Osteoporos Int 2012; 23: 811-820.
52. Hernlund E etal. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 2013; 8: 1-115.
53. Pike C etal. Direct and indirect costs of non-vertebral fracture patients with osteoporosis in the US. Pharmacoeconomics 2010; 28: 395-409.
54. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. http://nof.org/files/nof/public/content/file/950/upload/523.pdf (accessed 22 June 2014).
55. Zahoor SAU. Prevalence of osteoporosis in postmenopausal women visiting police & services hospital, PESHAWAR, NWFP. JPMI 2010; 24: 4-8.
56. Ejaz SMA etal. Prevalence of osteoporosis and osteopenia among Pakistani pre and post menopausal women. IOSR J Dent Med Sci (JDMS) 2012; 2: 12-17.
57. Habiba U etal. Predisposition to osteoporosis in post-menopausal women. J Coll Physicians Surg Pak 2002; 12: 297-301.
58. Borgstrom F, Kanis JA. Health economics of osteoporosis. Best Pract Res Clin Endocrinol Metab 2008; 22: 885-900.
59. Joel ME, Le Gales C. Social and economic aspects of osteoporosis. Curr Opin Rheumatol 1998; 10: 362-367.
60. Carr AJ etal. Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey. Osteoporos Int 2006; 17: 1638-1644.
61. NICE. Osteoporosis: Assessing the Risk of Fragility Fracture. NICE Clinical Guideline 146. http://www.nice.org.uk/CG146 (accessed 22 June 2014).
62. Diab DL, Watts NB. Bisphosphonates in the treatment of osteoporosis. Endocrinol Metab Clin North Am 2012; 41: 487-506.
63. McClung M etal. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med 2013; 126: 13-20.
64. Ideguchi H etal. Persistence with bisphosphonate therapy including treatment courses with multiple sequential bisphosphonates in the real world. Osteoporos Int 2007; 18: 1421-1427.
65. Papaioannou A etal. Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int 2003; 14: 808-813.
66. Cramer JA etal. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005; 21: 1453-1460.
67. Huybrechts KF etal. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 2006; 38: 922-928.
68. Weycker D etal. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 2006; 17: 1645-1652.
69. Hiligsmann M etal. The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland. Value Health 2012; 15: 604-612.
70. Segal E etal. Compliance of osteoporotic patients with different treatment regimens. Isr Med Assoc J 2003; 5: 859-862.
71. Roughead EE etal. Bisphosphonate use and subsequent prescription of acid suppressants. Br J Clin Pharmacol 2004; 57: 813-816.
72. NHS UKMi. Is There an Interaction between Bisphosphonates and Proton Pump Inhibitors? http://www.google.co.uk/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0CCEQFjAA&url=http%3A%2F%2Fwww.medicinesresources.nhs.uk%2FGetDocument.aspx%3FpageId%3D792927&ei=TS-uVK2EBIS9UarzgJgL&usg=AFQjCNGmW60sHZDLyP584-GGENodqbEL-Q. (accessed 22 June 2014).
73. Gray SL etal. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med 2010; 170: 765-771.
74. Ding J etal. The relationship between proton pump inhibitor adherence and fracture risk in the elderly. Calcif Tissue Int 2014; 94: 597-607.
75. Lee J etal. A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate. J Gastroenterol 2013; 48: 1016-1022.
76. Nigussie WD. Patient counselling at dispensing of medicines in health care facility outpatient pharmacies of Bahir Dar city, Northwest Ethiopia. Sci J Public Health 2014; 2: 126-134.
77. World Health Organisation (WHO). How to Investigate Drug Use in Health Facilities Selected Drug Use Indicators. Geneva: World Health Organization, 1993. WHO/DAP/931:1-97.
78. Hogerzeil HV etal. Field tests for rational drug use in twelve developing countries. Lancet 1993; 342: 1408-1410.
79. Nizami SQ etal. Drug prescribing practices of general practitioners and paediatricians for childhood diarrhoea in Karachi, Pakistan. Soc Sci Med 1996; 42: 1133-1139.
80. Rush DN etal. Evaluation of calcium and vitamin D supplementation in bisphosphonate therapy. J Am Pharm Assoc (2003) 2007; 47: 725-728.
81. Eom CS etal. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ 2011; 183: 310-319.
82. Hajjar ER etal. Polypharmacy in elderly patients. Am J Geriatr Pharmacother 2007; 5: 345-351.
83. Patterson SM etal. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev 2012; 5: Cd008165.
84. Godman B etal. Improving the managed entry of new medicines: sharing experiences across Europe. Expert Rev Pharmacoecon Outcomes Res 2012; 12: 439-441.
85. Buck MD etal. Potentially inappropriate medication prescribing in outpatient practices: prevalence and patient characteristics based on electronic health records. Am J Geriatr Pharmacother 2009; 7: 84-92.
86. Hines LE, Murphy JE. Potentially harmful drug-drug interactions in the elderly: a review. Am J Geriatr Pharmacother 2011; 9: 364-377.
87. Najmi MH etal. Prescribing practices: an overview of three teaching hospitals in Pakistan. J Pak Med Assoc 1998; 48: 73-77.
88. Spurling GK etal. Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: a systematic review. PLoS Med 2010; 7: e1000352.
89. Baumgärtel C etal. What lessons can be learned from the launch of generic clopidogrel? GaBI J 2012; 1: 58-68.
90. Enwere OO etal. Drug prescribing pattern at the medical outpatient clinic of a tertiary hospital in southwestern Nigeria. Pharmacoepidemiol Drug Saf 2007; 16: 1244-1249.
91. CNET. PharmaGuide Pakistan. http://download.cnet.com/PharmaGuide-Pakistan-Edition/3000-2129_4-75843412.html (accessed 22 June 2014).
92. Abuelkhair M etal. Imperative to consider multiple initiatives to maximize prescribing efficiency from generic availability: case history from Abu Dhabi. Expert Rev Pharmacoecon Outcomes Res 2012; 12: 115-124.
93. Garuoliene K etal. European countries with small populations can obtain low prices for drugs: Lithuania as a case history. Expert Rev Pharmacoecon Outcomes Res 2011; 11: 343-349.
94. Avorn J, Solomon DH. Cultural and economic factors that (mis)-shape antibiotic use: the nonpharmacologic basis of therapeutics. Ann Intern Med 2000; 133: 128-135.
95. Hamm RM etal. Antibiotics and respiratory infections: are patients more satisfied when expectations are met? J Fam Pract 1996; 43: 56-62.
96. Mangione-Smith R etal. The relationship between perceived parental expectations and pediatrician antimicrobial prescribing behavior. Pediatrics 1999; 103: 711-718.
97. Saadat SMS, Qureshi A. Antibiotic prescription practice of dental practitioners in a public sector institute of Karachi. J Dow Univ Health Sci 2013; 7: 54-58.
98. Adriaenssens N etal. European Surveillance of Antimicrobial Consumption (ESAC): disease-specific quality indicators for outpatient antibiotic prescribing. BMJ Qual Saf 2011; Mar 21. [Epub ahead of print].
99. Formoso G etal. Feasibility and effectiveness of a low cost campaign on antibiotic prescribing in Italy: community level, controlled, non-randomised trial. BMJ 2013; 347: f5391.
100. Molstad S etal. Strama - a Swedish working model for containment of antibiotic resistance. Euro Surveill 2008; 13: 1-4.
101. Standing Medical Advisory Committee. The Path of Least Resistance. 1998. http://antibiotic-action.com/wp-content/uploads/2011/07/Standing-Medical-Advisory-Committee-The-path-of-least-resistance-1998.pdf (accessed 26 July 2014).
102. Molstad S et al. Sustained reduction of antibiotic use and low bacterial resistance: 10-year follow-up of the Swedish Strama programme. The Lancet infectious diseases. 2008; 8(2): 125-132.
103. World Health Organisation. Drug and Therapeutics Committees - A Practical Guide. http://apps.who.int/medicinedocs/pdf/s4882e/s4882e.pdf (accessed 30 June 2014).
104. McGettigan P etal. Prescribers prefer people: the sources of information used by doctors for prescribing suggest that the medium is more important than the message. Br J Clin Pharmacol 2001; 51: 184-189.
105. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA 2000; 283: 373-380.
106. Light DW etal. Institutional corruption of pharmaceuticals and the myth of safe and effective drugs. J Law Med Ethics 2013; 41: 590-600.
107. Yu SY etal. New anti-rebate legislation in South Korea. Appl Health Econ Health Policy 2013; 11: 311-318.
108. Brkicic LS etal. Initiatives to improve prescribing efficiency for drugs to treat Parkinson's disease in Croatia: influence and future directions. Expert Rev Pharmacoecon Outcomes Res 2012; 12: 373-384.